WuXi Launches Mobile App to Enable Chemistry-on-the-Go

SHANGHAI, Jan. 5, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations inChina and the United States, announced the launch of WuXi V-Lab, the first mobile app available to the global research community in need of small-molecule compound synthesis.  WuXi V-Lab allows customers to request organic compound synthesis through a mobile device with ease, speed, and flexibility. The application provides online functions for inquiry, quotation, order confirmation, project tracking, delivery confirmation, and payment. WuXi V-Lab can be downloaded to an Apple or Android mobile device at: http://www.wuxiapptec.com/WXVLab

"WuXi is one of the world's largest employers of chemists and a recognized leader in premier chemistry services," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "We are committed to integrating best-in-class R&D capabilities with cutting-edge mobile technologies to enable innovation-on-the-go by anyone, at any time, anywhere."

About WuXi PharmaTech  

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
+1 (201) 585-2048
[email protected]

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.